[{"data":1,"prerenderedAt":220},["ShallowReactive",2],{"drug-doxazosin":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":19,"regimens":57,"contraindications":101,"warnings":111,"renal":112,"monitoring":113,"interactions":114,"review":123,"examples":126,"atc":137,"iran":139,"links":163,"populations":180,"usApproval":215},"doxazosin",1,{"fa":7,"en":8},"دوکسازوسین","Doxazosin","cardiovascular",{"fa":11,"en":12},"آلفا-۱ بلاکر","Alpha-1 blocker",[14],{"name":15,"market":16},"Cardura","US",[18,7],"cardura",[20,33,41,49],{"id":21,"form":22,"route":23,"label":24,"concentration":25,"markets":28,"refs":29},"tab-1","tablet","oral","1 mg tablet (scored)",{"amount":5,"unit":26,"perUnit":22,"scored":27},"mg",true,[16],[30],{"source":31,"section":32},"fda-doxazosin","3",{"id":34,"form":22,"route":23,"label":35,"concentration":36,"markets":38,"refs":39},"tab-2","2 mg tablet (scored)",{"amount":37,"unit":26,"perUnit":22,"scored":27},2,[16],[40],{"source":31,"section":32},{"id":42,"form":22,"route":23,"label":43,"concentration":44,"markets":46,"refs":47},"tab-4","4 mg tablet (scored)",{"amount":45,"unit":26,"perUnit":22,"scored":27},4,[16],[48],{"source":31,"section":32},{"id":50,"form":22,"route":23,"label":51,"concentration":52,"markets":54,"refs":55},"tab-8","8 mg tablet (scored)",{"amount":53,"unit":26,"perUnit":22,"scored":27},8,[16],[56],{"source":31,"section":32},[58,82],{"id":59,"disease":59,"label":60,"population":63,"type":67,"unit":26,"dose":68,"refs":71,"notes":74},"bph",{"fa":61,"en":62},"BPH — شروع ۱ mg روزانه، دو برابر هر ۱ تا ۲ هفته تا حداکثر ۸ mg","BPH — start 1 mg daily, double every 1–2 weeks up to 8 mg",{"minAge":64},{"value":65,"unit":66},18,"year","titration",{"dividedDoses":5,"titration":69},{"start":5,"incrementEveryDays":70,"max":53},7,[72],{"source":31,"section":73},"2.2",[75],{"text":76,"refs":79},{"fa":77,"en":78},"افت فشار وضعیتی و غش با دوز اول یا افزایش دوز؛ فشار تا ۶ ساعت پایش شود. شروع شب‌هنگام بهتر است.","Postural hypotension and syncope with the first dose or dose increases; monitor BP for up to 6 h.",[80],{"source":31,"section":81},"2.1",{"id":83,"disease":84,"label":85,"population":88,"type":67,"unit":26,"dose":90,"refs":93,"notes":96},"htn","hypertension",{"fa":86,"en":87},"فشار خون — شروع ۱ mg روزانه، تا حداکثر ۱۶ mg","Hypertension — start 1 mg daily, up to 16 mg",{"minAge":89},{"value":65,"unit":66},{"dividedDoses":5,"titration":91},{"start":5,"incrementEveryDays":70,"max":92},16,[94],{"source":31,"section":95},"2.3",[97],{"text":98,"refs":99},{"fa":77,"en":78},[100],{"source":31,"section":81},[102],{"id":103,"severity":104,"text":105,"refs":108},"hyper","block",{"fa":106,"en":107},"حساسیت به کینازولین‌ها (پرازوسین، ترازوسین، دوکسازوسین).","Hypersensitivity to quinazolines (prazosin, terazosin, doxazosin).",[109],{"source":31,"section":110},"4",[],[],[],[115],{"with":116,"text":117,"refs":120},"pde5",{"fa":118,"en":119},"مهارکننده‌های PDE5: افت فشار علامت‌دار.","PDE5 inhibitors: symptomatic hypotension.",[121],{"source":31,"section":122},"5",{"status":124,"reviewer":125,"date":125},"unverified",null,[127,132],{"regimen":59,"formulation":21,"input":128,"expect":131},{"ageYears":129,"weightKg":130},65,75,{"perDose":5,"tabletsPerDoseRounded":5},{"regimen":83,"formulation":21,"input":133,"expect":136},{"ageYears":134,"weightKg":135},55,80,{"perDose":5,"tabletsPerDoseRounded":5},[138],"C02CA04",{"status":140,"forms":141,"refs":158},"registered",[142,146,150,154],{"code":143,"en":144,"fa":145},"11246","DOXAZOSIN 1MG TAB","قرص دوکسازوسین ۱ میلی‌گرم",{"code":147,"en":148,"fa":149},"06773","DOXAZOSIN 2MG TAB","قرص دوکسازوسین ۲ میلی‌گرم",{"code":151,"en":152,"fa":153},"20964","DOXAZOSIN 4MG CAP","کپسول دوکسازوسین ۴ میلی‌گرم",{"code":155,"en":156,"fa":157},"05059","DOXAZOSIN 4MG TAB","قرص دوکسازوسین ۴ میلی‌گرم",[159],{"source":160,"section":161,"url":162},"darooyab-generic","G-1654\u002FDoxazosin","https:\u002F\u002Fwww.darooyab.ir\u002FG-1654\u002FDoxazosin",[164,168,172,175,178],{"kind":165,"url":166,"label":167},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=075580","ANDA075580",{"kind":169,"url":170,"label":171},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=4fa5c2f7-cda9-56cd-622f-b3d05dc7c94b","FDA Doxazosin",{"kind":173,"url":174,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa693045.html",{"kind":176,"url":177,"label":138},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=C02CA04",{"kind":179,"url":162,"label":8},"darooyab",{"pregnancy":181,"lactation":190,"pediatric":198,"geriatric":207},{"level":182,"text":183,"quote":186,"refs":187},"caution",{"fa":184,"en":185},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary The limited available data with doxazosin tablets in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage.",[188],{"source":31,"section":189},"8.1",{"level":182,"text":191,"quote":194,"refs":195},{"fa":192,"en":193},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is limited information on the presence of doxazosin in human milk [ see Data ].",[196],{"source":31,"section":197},"8.2",{"level":199,"text":200,"quote":203,"refs":204},"not-established",{"fa":201,"en":202},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","The safety and effectiveness of doxazosin tablets have not been established in children.",[205],{"source":31,"section":206},"8.4",{"level":182,"text":208,"quote":211,"refs":212},{"fa":209,"en":210},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.",[213],{"source":31,"section":214},"8.5",{"kind":216,"refs":217,"id":167},"ANDA",[218],{"source":31,"section":219},"SPL approval \u002F marketing category",1792156175824]